Apremilast, competitive inhibitor of phosphodiesterase 4 (PDE4), has been recently introduced in the treatment of adult PsA patients. Its efficacy and safety has been assessed in the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy program, including four phase 3, multicentre, randomized, double-blind, placebo-controlled, parallelgroup trials. According to EULAR recommendations, US with power Doppler (PD) is able to detect joint inflammation and may be used to monitor PsA activity. Here, the US early response to apremilast in a PsA cohort was evaluated.
Early response to apremilast treatment in psoriatic arthritis: a real-life ultrasonographic follow-up study
Perricone, Carlo;
2018
Abstract
Apremilast, competitive inhibitor of phosphodiesterase 4 (PDE4), has been recently introduced in the treatment of adult PsA patients. Its efficacy and safety has been assessed in the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy program, including four phase 3, multicentre, randomized, double-blind, placebo-controlled, parallelgroup trials. According to EULAR recommendations, US with power Doppler (PD) is able to detect joint inflammation and may be used to monitor PsA activity. Here, the US early response to apremilast in a PsA cohort was evaluated.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
